Condition
Oculocutaneous Albinism
Total Trials
6
Recruiting
1
Active
1
Completed
3
Success Rate
60.0%-27% vs avg
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
33.3%
2 terminated out of 6 trials
Success Rate
60.0%
-26.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
3 of 3 completed with results
Key Signals
3 with results60% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Completed3
Terminated2
Recruiting1
Trial Success Rate
60.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT06138509RecruitingPrimary
Peripheral Serotonin and Albinism
NCT00808106CompletedPrimary
Clinical, Cellular, and Molecular Investigation Into Oculocutaneous Albinism
NCT04068961CompletedPrimary
New Strategies of Genetic Study of Patients With Oculocutaneous Albinism
NCT01663935Phase 2Terminated
Vision Response to Dopamine Replacement
NCT00001596Phase 2Completed
Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
NCT00467831Phase 1Terminated
Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
Showing all 6 trials